Literature DB >> 17763992

The differential contribution of dopamine D(1) and D (2) receptors to mu-opioidergic immunomodulation.

M A Cheido1, G V Idova.   

Abstract

Activation of mu-opioid receptors (mu-OR) by the highly selective agonist DAGO (100 microg/kg) significantly increased the immune response in CBA mice. This effect of the mu agonist was prevented by prior blockade of dopamine D(2) receptors with haloperidol (2 mg/kg). In contrast, the selective D(1) receptor antagonist SCH 23390 (1 mg/kg) had no effect on the nature of the immune reaction in response to antigen (sheep erythrocytes, 5 x 10(8) cells). However, blockade of both types of dopamine receptor led to the same effect--immunosuppression. These data lead to the suggestion that D(1) and D(2) receptors make different contributions to modulating immunogenesis on activation of mu-OR.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17763992     DOI: 10.1007/s11055-007-0073-9

Source DB:  PubMed          Journal:  Neurosci Behav Physiol        ISSN: 0097-0549


  33 in total

1.  Region specific increase of dopamine receptor D1/D2 mRNA expression in the brain of mu-opioid receptor knockout mice.

Authors:  Y Park; I K Ho; L W Fan; H H Loh; K H Ko
Journal:  Brain Res       Date:  2001-03-16       Impact factor: 3.252

Review 2.  Dopamine, a neurotransmitter, influences the immune system.

Authors:  S Basu; P S Dasgupta
Journal:  J Neuroimmunol       Date:  2000-01-24       Impact factor: 3.478

Review 3.  Opioids, opioid receptors, and the immune response.

Authors:  L McCarthy; M Wetzel; J K Sliker; T K Eisenstein; T J Rogers
Journal:  Drug Alcohol Depend       Date:  2001-04-01       Impact factor: 4.492

Review 4.  Dopaminergic stimulation of the immune reaction: interaction of serotoninergic and dopaminergic systems in neuroimmunomodulation.

Authors:  L Devoino; E Alperina; G Idova
Journal:  Int J Neurosci       Date:  1988-06       Impact factor: 2.292

5.  A method of increased sensitivity for detecting single antibody-forming cells.

Authors:  A J Cunningham
Journal:  Nature       Date:  1965-09-04       Impact factor: 49.962

6.  Involvement of opioid mu1-receptors in opioid-induced acceleration of striatal and limbic dopaminergic transmission.

Authors:  T P Piepponen; A Honkanen; T Kivastik; A Zharkovsky; A Turtia; J A Mikkola; L Ahtee
Journal:  Pharmacol Biochem Behav       Date:  1999-06       Impact factor: 3.533

7.  Immunomodulatory activity of kappa-, mu-, and delta-selective opioid compounds.

Authors:  T J Rogers; D D Taub; T K Eisenstein; E B Geller; M W Adler
Journal:  NIDA Res Monogr       Date:  1990

8.  Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

9.  Opioid antagonist naltrexone disrupts feedback interaction between mu and delta opioid receptors in splenocytes to prevent alcohol inhibition of NK cell function.

Authors:  Nadka I Boyadjieva; Kirti Chaturvedi; Michael M Poplawski; Dipak K Sarkar
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

10.  Analogues of beta-LPH61-64 possessing selective agonist activity at mu-opiate receptors.

Authors:  B K Handa; A C Land; J A Lord; B A Morgan; M J Rance; C F Smith
Journal:  Eur J Pharmacol       Date:  1981-04-09       Impact factor: 4.432

View more
  2 in total

1.  Haloperidol disrupts opioid-antinociceptive tolerance and physical dependence.

Authors:  Cheng Yang; Yan Chen; Lei Tang; Zaijie Jim Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-03-24       Impact factor: 4.030

2.  Prevalence of elevated serum anti-N-methyl-D-aspartate receptor antibody titers in patients presenting exclusively with psychiatric symptoms: a comparative follow-up study.

Authors:  Yoshihito Ando; Haruo Shimazaki; Katsutoshi Shiota; Syuichi Tetsuka; Koichi Nakao; Tatsuhiro Shimada; Kazumi Kurata; Jinichi Kuroda; Akihiro Yamashita; Hayato Sato; Mamoru Sato; Shinkichi Eto; Yasunori Onishi; Keiko Tanaka; Satoshi Kato
Journal:  BMC Psychiatry       Date:  2016-07-08       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.